Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06384716
Other study ID # CEB
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 19, 2024
Est. completion date September 1, 2024

Study information

Verified date February 2024
Source Universidad Europea de Madrid
Contact Cecilia Estrada-Barranco, PhD
Phone 686166483
Email cecilia.estrada@universidadeuropea.es
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Given the structural relationship of the CORE as a whole, in this study we propose an intervention based on the global motor control of all the structures that make up the CORE to assess its effectiveness on urinary incontinence, sexual dysfunction and balance, as well as its relationship with respiratory function. According to our hypothesis, a global intervention could also be taken into account during conventional treatment in the future, helping to prevent genitourinary dysfunctions derived from alterations in motor control.


Description:

Main objective: To establish the effect of core motor control training on pelvic floor functionality in patients with multiple sclerosis. Specific objective: To assess the effect of core motor control training on urinary incontinence. - To assess the effect of core motor control training on urinary incontinence in patients with multiple sclerosis. - To assess the effect of core motor control training on quality of life in patients with multiple sclerosis. - To assess the effect of core motor control training on sexual dysfunction in patients with multiple sclerosis. - To assess the effect of core motor control training on balance in patients with multiple sclerosis. - To test the relationship between respiratory functionality and pelvic floor dysfunctions in patients with multiple sclerosis.


Recruitment information / eligibility

Status Recruiting
Enrollment 32
Est. completion date September 1, 2024
Est. primary completion date July 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - - Age between 18 and 70 years. - Confirmed diagnosis of Multiple Sclerosis based on McDonald criteria, with an evolution time of more than two years (remitting or progressive) (24). - Multiple Sclerosis Disability Status Scale (EDSS) score between 2 (minimal disability in one of the functional systems), and 7.5 (inability to take more than a few steps. Limited to wheelchair and transfer support. Ability to move the chair, but not all day if the chair is conventional and lacks a motor) (25, 26). - Stable medical treatment for at least six months prior to surgery (26). - Absence of cognitive impairment, with ability to understand instructions and score 24 or higher on the Minimental Test (27). - Urinary incontinence as a consequence of neurological involvement. Exclusion Criteria: - - Diagnosis of another neurological disease or musculoskeletal disorder other than MS. - Diagnosis of any cardiovascular, respiratory, genitourinary, metabolic or other conditions that may interfere with this study. - Having presented urinary incontinence prior to the diagnosis of MS. - Have suffered an exacerbation or hospitalisation in the last 3 months before starting the assessment protocol, or during the therapeutic intervention process. - Have received a course of intravenous or oral steroids 6 months prior to the start of the assessment protocol and within the intervention period of the study duration.

Study Design


Intervention

Other:
rehabilitation programme based on motor control of core muscles
The exercises performed during the intervention aim to improve the functionality of MS patients and to assess how this can improve pelvic floor health, quality of life, sexual health and urinary incontinence. A specific exercise programme has been designed and will be carried out by physiotherapists specialised in neurological physiotherapy for this purpose. The ultimate aim of the research is to be able to benefit other MS patients from our findings and to propose specific interventions in these areas. However, it is possible that no direct benefit will be obtained after the intervention. At the end of the research you will be informed, if you wish, about the main results and general conclusions of the study. The study does not pose any risk to your health as it is a non-invasive study and no harmful or deleterious action is incurred for the additional collection of the necessary records.

Locations

Country Name City State
Spain Cecilia Estrada Barranco Madrid

Sponsors (1)

Lead Sponsor Collaborator
Universidad Europea de Madrid

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in the percentage of initial and final maximum activity of the pelvic floor muscles. EMG 8 weeks
Primary - Differences between the initial and final thickness of the oblique abdominis and transverse oblique muscles by ultrasound. US 8 weeks
Primary - Differences in the assessment of health-related quality of life before and after the intervention measured with the I-QOL questionnaire. IQOL 8 weeks
Primary - Differences in the assessment of female UI before and after intervention using the I-CIQ questionnaire I-CIQ 8 weeks
Secondary - Difference in the percentage of initial and final maximum activity of the paravertebral musculature activity. EMG 8 weeks
Secondary - Differences between initial and final amplitude of initial and final diaphragmatic excursion by ultrasound. US 8 weeks
Secondary - Difference between initial and final FVC/- Differences between the initial and final peak expired volume (FEV1) spirometry 8 weeks
Secondary differences between peak expiratory pressure (PEM) and minimum initial and end inspiratory pressure (MIP). PIM/PEM 8 weeks
Secondary balance trunk control test and Berg Balance test 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4